Nuclear morphometry, epigenetic changes, and clinical relevance in prostate cancer

Advances in Experimental Medicine and Biology

Volumn 773, Issue , 2014, Pages 77-99

  Veltri, Robert W ^a   Christudass, Christhunesa S ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

Epigenetics; Nuclear morphology; Nuclear roundness; Prostate cancer

Indexed keywords

DNA; HISTONE DEACETYLASE; LAMIN; NUCLEAR PROTEIN; POLYCOMB GROUP PROTEIN;

ARTICLE; CELL DIFFERENTIATION; CELL FUNCTION; CELL NUCLEUS MEMBRANE; CELL PROLIFERATION; CELL STRUCTURE; CHROMOSOME STRUCTURE; CYTOARCHITECTURE; DNA METHYLATION; EPIGENETICS; GENOMIC INSTABILITY; HISTONE ACETYLATION; HUMAN; MOLECULAR DYNAMICS; MOLECULAR GENETICS; NONHUMAN; NUCLEAR PORE COMPLEX; PRIORITY JOURNAL; PROSTATE CANCER;

CELL NUCLEUS; CELL NUCLEUS SHAPE; EPIGENESIS, GENETIC; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 84934434358     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4899-8032-8_4     Document Type: Article

References (110)

1. Virchow R (1863) Cellular pathology as based upon physiological and pathological histology. J B Lippincott, Philadelphia, PA
2. Beale L (1860) Examination of sputum from a case of cancer of the pharynx and the adjacent parts. Arch Med (Lond) 2:44-46
3. Long SR, Cohen MB (1993) Classics in cytology. VI: the early cytologic discoveries of Lionel S. Beale. Diagn Cytopathol 9(5):595-598
4. Cremer T, Cremer C (2006) Rise, fall and resurrection of chromosome territories: a historical perspective. Part II. Fall and resurrection of chromosome territories during the 1950s to 1980s. Part III. Chromosome territories and the functional nuclear architecture: experiments and models from the 1990s to the present. Eur J Histochem 50(4):223-272
5. Cremer T, Cremer C (2006) Rise, fall and resurrection of chromosome territories: a historical perspective. Part I. The rise of chromosome territories. Eur J Histochem 50(3):161-176
6. Boveri T (2008) Concerning the origin of malignant tumours by Theodor Boveri. Translated and annotated by Henry Harris. J Cell Sci 121(Suppl 1):1-84
7. Veltri RW, Christudass CS, Isharwal S (2012) Nuclear morphometry, nucleomics and prostate cancer progression. Asian J Androl 14(3):375-384
8. Cremer T, Cremer M (2010) Chromosome territories. Cold Spring Harb Perspect Biol 2(3):a003889
9. Veltri RW, Partin AW, Miller CM (2005) Quantitative nuclear grade (QNG): the clinical applications of the quantitative measurement of nuclear structure using image analysis. In: Kelloff GJ, Hawk ET, Sigman CC (eds) Cancer chemoprevention. Humana Press, Totowa, NJ, pp 97-108
10. Sheehan DC, Hrapchak BB (1980) Theory and practice of histotechnology, 2nd edn. Battelle, Columbus, OH
11. Papanicolaou GN, Traut HF (1997) The diagnostic value of vaginal smears in carcinoma of the uterus. 1941. Arch Pathol Lab Med 121(3):211-224
12. Gill JE, Jotz MM (1976) Further observations on the chemistry of pararosaniline-Feulgen staining. Histochemistry 46(2):147-160
13. Schulte E, Wittekind D (1989) Standardization of the Feulgen-Schiff technique. Staining characteristics of pure fuchsin dyes; a cytophotometric investigation. Histochemistry 91(4):321-331
14. Gleason DF (1966) Classifi cation of prostatic carcinomas. Cancer Chemother Rep 50(3):125-128
15. Gleason DF (1992) Histologic grading of prostate cancer: a perspective. Hum Pathol 23(3):273-279
16. Epstein JI (2010) An update of the Gleason grading system. J Urol 183(2):433-440
17. Brimo F et al (2013) Contemporary grading for prostate cancer: implications for patient care. Eur Urol 63(5):892-901
18. Diamond DA et al (1982) Computerized image analysis of nuclear shape as a prognostic factor for prostatic cancer. Prostate 3(4):321-332
19. Benson MC, McDougal DC, Coffey DS (1984) The application of perpendicular and forward light scatter to assess nuclear and cellular morphology. Cytometry 5(5):515-522
20. Benson MC, McDougal DC, Coffey DS (1984) The use of multiparameter fl ow cytometry to assess tumor cell heterogeneity and grade prostate cancer. Prostate 5(1):27-45
21. Mohler JL et al (1988) Nuclear roundness factor measurement for assessment of prognosis of patients with prostatic carcinoma. II. Standardization of methodology for histologic sections. J Urol 139(5):1085-1090
22. Mohler JL et al (1988) Nuclear roundness factor measurement for assessment of prognosis of patients with prostatic carcinoma. I. Testing of a digitization system. J Urol 139(5): 1080-1084
23. Partin AW et al (1989) A comparison of nuclear morphometry and Gleason grade as a predictor of prognosis in stage A2 prostate cancer: a critical analysis. J Urol 142(5):1254-1258
24. Isharwal S et al (2008) p300 (histone acetyltransferase) biomarker predicts prostate cancer biochemical recurrence and correlates with changes in epithelia nuclear size and shape. Prostate 68(10):1097-1104
25. Badalament RA et al (1996) An algorithm for predicting nonorgan confi ned prostate cancer using the results obtained from sextant core biopsies with prostate specifi c antigen level. J Urol 156(4):1375-1380
26. Veltri RW et al (2002) Prediction of pathological stage in patients with clinical stage T1c prostate cancer: the new challenge. J Urol 168(1):100-104
27. Veltri RW et al (1996) Ability to predict biochemical progression using Gleason score and a computer-generated quantitative nuclear grade derived from cancer cell nuclei. Urology 48(5):685-691
28. Khan MA et al (2003) Quantitative alterations in nuclear structure predict prostate carcinoma distant metastasis and death in men with biochemical recurrence after radical prostatectomy. Cancer 98(12):2583-2591
29. Veltri RW et al (2004) Ability to predict metastasis based on pathology fi ndings and alterations in nuclear structure of normal-appearing and cancer peripheral zone epithelium in the prostate. Clin Cancer Res 10(10):3465-3473
30. Kortenhorst MS et al (2009) Valproic acid causes dose-and time-dependent changes in nuclear structure in prostate cancer cells in vitro and in vivo. Mol Cancer Ther 8(4):802-808
31. Doyle S et al (2010) A boosted Bayesian multiresolution classifi er for prostate cancer detection from digitized needle biopsies. IEEE Trans Biomed Eng 59(5):1205-1218
32. Madabhushi A et al (2011) Computer-aided prognosis: predicting patient and disease outcome via quantitative fusion of multi-scale, multi-modal data. Comput Med Imaging Graph 35(7-8):506-514
33. Gao M, Bridgman P, Kumar S (2003) Computer aided prostate cancer diagnosis using image enhancement and JPEG2000. In: Proceedings of the SPIE Annual Meeting, 2003, San Diego, CA
34. Tiwari P et al (2011) Multi-modal data fusion schemes for integrated classifi cation of imaging and non-imaging biomedical data. In: ISBI, 2011, Chicago, IL, pp 165-168
35. Ali S et al (2011) Adaptive energy selective active contour with shape priors for nuclear segmentation and Gleason grading of prostate cancer. Med Image Comput Comput Assist Interv 14(Pt 1):661-669
36. Doyle S et al (2007) Automated grading of prostate cancer using architectural and textural image features. In: ISBI, 2007, Arlington, VA, pp 1284-1287
37. Huang PW, Lee CH (2009) Automatic classifi cation for pathological prostate images based on fractal analysis. IEEE Trans Med Imaging 28(7):1037-1050
38. Khurd P et al (2010) Computer-aided Gleason grading of prostate cancer histopathological images using texton forests. In: ISBI, 2010, Rotterdam, pp 636-639
39. Khurd P et al (2011) Network cycle features: application to computer-aided Gleason grading of prostate cancer histopathological images. In: ISBI, 2011, Chicago, IL, pp 1632-1636
40. Naik S et al (2008) Automated gland and nuclei segmentation for grading of prostate and breast cancer histopathology. In: ISBI, Paris, 2008, pp 284-287
41. Nguyen K, Jain AK, Allen RL (2010) Automated gland segmentation and classifi cation for gleason grading of prostate tissue images. In: 20th international conference on pattern recognition (ICPR), 2010, Istanbul, pp 1497-1500
42. Ou Y et al (2009) Sampling the spatial patterns of cancer: optimized biopsy procedures for estimating prostate cancer volume and Gleason Score. Med Image Anal 13(4):609-620
43. Tabesh A et al (2007) Multifeature prostate cancer diagnosis and Gleason grading of histological images. IEEE Trans Med Imaging 26(10):1366-1378
44. Yoon HY et al (2011) Cardinal multiridgelet-based prostate cancer histological image classifi cation for Gleason grading. In: BIBM, 2011, Atlanta, GA, pp 315-320
45. Chow KH, Factor RE, Ullman KS (2012) The nuclear envelope environment and its cancer connections. Nat Rev Cancer 12(3):196-209
46. de Las Heras JI, Batrakou DG, Schirmer EC (2013) Cancer biology and the nuclear envelope: a convoluted relationship. Semin Cancer Biol 23(2):125-137
47. Verstraeten VL et al (2007) The nuclear envelope, a key structure in cellular integrity and gene expression. Curr Med Chem 14(11):1231-1248
48. Hozák P et al (1995) Lamin proteins form an internal nucleoskeleton as well as a peripheral lamina in human cells. J Cell Sci 108(Pt 2):635-644
49. Naetar N, Foisner R (2009) Lamin complexes in the nuclear interior control progenitor cell proliferation and tissue homeostasis. Cell Cycle 8(10):1488-1493
50. Berezney R, Coffey DS (1974) Identifi cation of a nuclear protein matrix. Biochem Biophys Res Commun 60(4):1410-1417
51. Coffey DS (2002) Nuclear matrix proteins as proteomic markers of preneoplastic and cancer lesions: commentary re: G. Brunagel et al., nuclear matrix protein alterations associated with colon cancer metastasis to the liver.
52. Clin. Cancer Res., 8: 3039-3045, 2002. Clin Cancer Res 8(10):3031-3033
53. Getzenberg RH, Coffey DS (2011) Changing the energy habitat of the cancer cell in order to impact therapeutic resistance. Mol Pharm 8(6):2089-2093
54. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646-674
55. He S et al (2008) Chromatin organization and nuclear microenvironments in cancer cells. J Cell Biochem 104(6):2004-2015
56. Podlaha O et al (2012) Evolution of the cancer genome. Trends Genet 28(4):155-163
57. Schetter AJ, Heegaard NH, Harris CC (2010) Infl ammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways. Carcinogenesis 31(1):37-49
58. Strahl BD, Allis CD (2000) The language of covalent histone modifi cations. Nature 403(6765):41-45
59. Turner BM (2011) Environmental sensing by chromatin: an epigenetic contribution to evolutionary change. FEBS Lett 585(13):2032-2040
60. Wu JI, Lessard J, Crabtree GR (2009) Understanding the words of chromatin regulation. Cell 136(2):200-206
61. Zhang Y, Reinberg D (2001) Transcription regulation by histone methylation: interplay between different covalent modifi cations of the core histone tails. Genes Dev 15(18): 2343-2360
62. Sasaki M et al (2002) Methylation and inactivation of estrogen, progesterone, and androgen receptors in prostate cancer. J Natl Cancer Inst 94(5):384-390
63. Suzuki H, Ito H (1999) Role of androgen receptor in prostate cancer. Asian J Androl 1(3):81-85
64. Tropberger P et al (2013) Regulation of transcription through acetylation of H3K122 on the lateral surface of the histone octamer. Cell 152(4):859-872
65. Jones PA, Baylin SB (2002) The fundamental role of epigenetic events in cancer. Nat Rev Genet 3(6):415-428
66. Cai C et al (2011) Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specifi c demethylase 1. Cancer Cell 20(4):457-471
67. Chlenski A et al (2001) Androgen receptor expression in androgen-independent prostate cancer cell lines. Prostate 47(1):66-75
68. Aryee MJ et al (2013) DNA methylation alterations exhibit intraindividual stability and interindividual heterogeneity in prostate cancer metastases. Sci Transl Med 5(169):169-10
69. Jarrard DF et al (1998) Methylation of the androgen receptor promoter CpG island is associated with loss of androgen receptor expression in prostate cancer cells. Cancer Res 58(23):5310-5314
70. Izbicka E et al (1999) 5,6 Dihydro-5′-azacytidine (DHAC) restores androgen responsiveness in androgen-insensitive prostate cancer cells. Anticancer Res 19(2A):1285-1291
71. Seligson DB et al (2005) Global histone modifi cation patterns predict risk of prostate cancer recurrence. Nature 435(7046):1262-1266
72. Bianco-Miotto T et al (2010) Global levels of specifi c histone modifi cations and an epigenetic gene signature predict prostate cancer progression and development. Cancer Epidemiol Biomarkers Prev 19(10):2611-2622
73. Watson JA et al (2010) Hyperacetylation in prostate cancer induces cell cycle aberrations, chromatin reorganization and altered gene expression profi les. J Cell Mol Med 14(6B): 1668-1682
74. Malik G et al (2007) SELDI protein profi ling of dunning R-3327 derived cell lines: identifi cation of molecular markers of prostate cancer progression. Prostate 67(14):1565-1575
75. Huisman A et al (2007) Discrimination between benign and malignant prostate tissue using chromatin texture analysis in 3-D by confocal laser scanning microscopy. Prostate 67(3):248-254
76. Li LC, Carroll PR, Dahiya R (2005) Epigenetic changes in prostate cancer: implication for diagnosis and treatment. J Natl Cancer Inst 97(2):103-115
77. Brock HW, van Lohuizen M (2001) The Polycomb group-no longer an exclusive club? Curr Opin Genet Dev 11(2):175-181
78. Jacobs JJ, van Lohuizen M (2002) Polycomb repression: from cellular memory to cellular proliferation and cancer. Biochim Biophys Acta 1602(2):151-161
79. Czermin B et al (2002) Drosophila enhancer of Zeste/ESC complexes have a histone H3 methyltransferase activity that marks chromosomal Polycomb sites. Cell 111(2):185-196
80. Varambally S et al (2002) The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419(6907):624-629
81. van der Vlag J, Otte AP (1999) Transcriptional repression mediated by the human polycombgroup protein EED involves histone deacetylation. Nat Genet 23(4):474-478
82. Yu J et al (2007) A polycomb repression signature in metastatic prostate cancer predicts cancer outcome. Cancer Res 67(22):10657-10663
83. Bryant RJ et al (2008) The Polycomb Group protein EZH2 regulates actin polymerization in human prostate cancer cells. Prostate 68(3):255-263
84. Bettinger BT, Gilbert DM, Amberg DC (2004) Actin up in the nucleus. Nat Rev Mol Cell Biol 5(5):410-415
85. Su IH et al (2005) Polycomb group protein ezh2 controls actin polymerization and cell signaling. Cell 121(3):425-436
86. Tan J et al (2007) Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev 21(9):1050-1063
87. Chase A, Cross NC (2011) Aberrations of EZH2 in cancer. Clin Cancer Res 17(9): 2613-2618
88. Laitinen S et al (2008) EZH2, Ki-67 and MCM7 are prognostic markers in prostatectomy treated patients. Int J Cancer 122(3):595-602
89. Jhavar S et al (2009) Biopsy tissue microarray study of Ki-67 expression in untreated, localized prostate cancer managed by active surveillance. Prostate Cancer Prostatic Dis 12(2):143-147
90. Veltri RW et al (2010) Nuclear roundness variance predicts prostate cancer progression, metastasis, and death: a prospective evaluation with up to 25 years of follow-up after radical prostatectomy. Prostate 70(12):1333-1339
91. Cao R et al (2002) Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science 298(5595):1039-1043
92. Bektas S et al (2009) The relation between Gleason score, and nuclear size and shape factors in prostatic adenocarcinoma. Turk J Med Sci 39(3):381-387
93. Debes JD et al (2005) p300 modulates nuclear morphology in prostate cancer. Cancer Res 65(3):708-712
94. Wang Z et al (2008) Combinatorial patterns of histone acetylations and methylations in the human genome. Nat Genet 40(7):897-903
95. Imbalzano KM et al (2013) Nuclear shape changes are induced by knockdown of the SWI/SNF ATPase BRG1 and are independent of cytoskeletal connections. PLoS One 8(2):e55628
96. Chernov IP, Akopov SB, Nikolaev LG (2004) Structure and functions of nuclear matrix associated regions (S/MARs). Russ J Bioorg Chem 30(1):1-11
97. Elcock LS, Bridger JM (2008) Exploring the effects of a dysfunctional nuclear matrix. Biochem Soc Trans 36(Pt 6):1378-1383
98. Nickerson J (2001) Experimental observations of a nuclear matrix. J Cell Sci 114(Pt 3): 463-474
99. Postnikov Y, Bustin M (2010) Regulation of chromatin structure and function by HMGN proteins. Biochim Biophys Acta 1799(1-2):62-68
100. Dechat T et al (2008) Nuclear lamins: major factors in the structural organization and function of the nucleus and chromatin. Genes Dev 22(7):832-853
101. Prokocimer M et al (2009) Nuclear lamins: key regulators of nuclear structure and activities. J Cell Mol Med 13(6):1059-1085
102. Stuurman N, Heins S, Aebi U (1998) Nuclear lamins: their structure, assembly, and interactions. J Struct Biol 122(1-2):42-66
103. Gonzalez-Suarez I et al (2009) Novel roles for A-type lamins in telomere biology and the DNA damage response pathway. EMBO J 28(16):2414-2427
104. Butler JT et al (2009) Changing nuclear landscape and unique PML structures during early epigenetic transitions of human embryonic stem cells. J Cell Biochem 107(4):609-621
105. Goldman RD et al (2002) Nuclear lamins: building blocks of nuclear architecture. Genes Dev 16(5):533-547
106. Coradeghini R et al (2006) Differential expression of nuclear lamins in normal and cancerous prostate tissues. Oncol Rep 15(3):609-613
107. Skvortsov S et al (2011) Proteomics profi ling of microdissected low-and high-grade prostate tumors identifi es Lamin A as a discriminatory biomarker. J Proteome Res 10(1):259-268
108. Kong L et al (2012) Lamin A/C protein is overexpressed in tissue-invading prostate cancer and promotes prostate cancer cell growth, migration and invasion through the PI3K/AKT/PTEN pathway. Carcinogenesis 33(4):751-759
109. Foster CR et al (2010) Lamins as cancer biomarkers. Biochem Soc Trans 38(Pt 1):297-300
110. Reddy KL, Feinberg AP (2013) Higher order chromatin organization in cancer. Semin Cancer Biol 23(2):109-115